Literature DB >> 9092534

Inhibition of neutrophil serine proteinases by suramin.

M Cadène1, J Duranton, A North, M Si-Tahar, M Chignard, J G Bieth.   

Abstract

Suramin, a hexasulfonated naphtylurea recently used as an anti-tumor drug, is a potent inhibitor of human neutrophil elastase, cathepsin G, and proteinase 3. The complexes it forms with these enzymes are partially active on synthetic substrates, but full inhibition takes place when elastase activity is measured with fibrous elastin or when cathepsin G activity is measured using platelet aggregation. One molecule of elastase binds four molecules of suramin with a Ki of 2 x 10(-7) M as determined by enzyme inhibition or intrinsic fluorescence enhancement of suramin. The binding curves show no sign of cooperativity or anticooperativity. The Ki for the complexes with cathepsin G and proteinase 3 are 8 x 10(-8) and 5 x 10(-7) M, respectively. Ionic strength increases the Ki of the elastase-suramin complex in a way that suggests that four of the six sulfonate groups of suramin form ionic interactions with basic residues of the enzyme and that at saturation almost all arginines of elastase form salt bridges with suramin. The neutrophil proteinase-inhibitory activity of suramin might be used to prevent tissue destruction and thrombus formation in diseases where massive infiltration and activation of neutrophils take place.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9092534     DOI: 10.1074/jbc.272.15.9950

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  10 in total

1.  Endothelium-dependent relaxation induced by cathepsin G in porcine pulmonary arteries.

Authors:  E Glusa; C Adam
Journal:  Br J Pharmacol       Date:  2001-06       Impact factor: 8.739

Review 2.  New therapies for chronic obstructive pulmonary disease.

Authors:  P J Barnes
Journal:  Thorax       Date:  1998-02       Impact factor: 9.139

Review 3.  100 Years of Suramin.

Authors:  Natalie Wiedemar; Dennis A Hauser; Pascal Mäser
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

4.  A novel bioluminescent protease assay using engineered firefly luciferase.

Authors:  Susan S Wigdal; Jessica L Anderson; Gediminas J Vidugiris; John Shultz; Keith V Wood; Frank Fan
Journal:  Curr Chem Genomics       Date:  2008-10-17

Review 5.  alpha1-Antitrypsin deficiency . 6: new and emerging treatments for alpha1-antitrypsin deficiency.

Authors:  R A Sandhaus
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

6.  The effect of suramin on the resorption of bovine nasal cartilage.

Authors:  C L Lewis; A Frazer; R G Russell; R A Bunning
Journal:  Inflammopharmacology       Date:  1999       Impact factor: 4.473

Review 7.  Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations.

Authors:  C M Greene; S D W Miller; T Carroll; C McLean; M O'Mahony; M W Lawless; S J O'Neill; C C Taggart; N G McElvaney
Journal:  J Inherit Metab Dis       Date:  2008-01-16       Impact factor: 4.982

8.  Aggregated neutrophil extracellular traps limit inflammation by degrading cytokines and chemokines.

Authors:  Christine Schauer; Christina Janko; Luis E Munoz; Yi Zhao; Deborah Kienhöfer; Benjamin Frey; Michael Lell; Bernhard Manger; Jürgen Rech; Elisabeth Naschberger; Rikard Holmdahl; Veit Krenn; Thomas Harrer; Ivica Jeremic; Rostyslav Bilyy; Georg Schett; Markus Hoffmann; Martin Herrmann
Journal:  Nat Med       Date:  2014-04-28       Impact factor: 53.440

9.  Glycolipid-Dependent, Protease Sensitive Internalization of Pseudomonas aeruginosa Into Cultured Human Respiratory Epithelial Cells.

Authors:  Aufaugh Emam; William G Carter; Clifford Lingwood
Journal:  Open Microbiol J       Date:  2010-12-13

Review 10.  Urea-based anticancer agents. Exploring 100-years of research with an eye to the future.

Authors:  Roberta Listro; Giacomo Rossino; Federica Piaggi; Falilat Folasade Sonekan; Daniela Rossi; Pasquale Linciano; Simona Collina
Journal:  Front Chem       Date:  2022-09-15       Impact factor: 5.545

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.